CD8A and neoplasm: Seminal studies have demonstrated that targeting the A2AR axis can potently enhance T cell function and anti-tumor responses, where A2AR pharmacological blockade could augment the anti-tumor activity of immune checkpoint blockade through enhanced CD8+ T cell responses10,11.